Last reviewed · How we verify
JE vaccine
JE vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.
JE vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in endemic regions.
At a glance
| Generic name | JE vaccine |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Vaccine |
| Target | Japanese encephalitis virus envelope proteins |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated Japanese encephalitis virus or viral antigens that trigger both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and neutralize the virus upon natural exposure, preventing infection or reducing disease severity. The vaccine is typically administered as a series of doses to establish protective immunity.
Approved indications
- Prevention of Japanese encephalitis in endemic regions
Common side effects
- Injection site pain or swelling
- Fever
- Myalgia
- Headache
Key clinical trials
- Flavivirus Cross-priming Potential of IMOJEV (NA)
- Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas (PHASE4)
- A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis. (PHASE3)
- Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 (PHASE3)
- Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 (PHASE3)
- Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 (PHASE3)
- Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity (NA)
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JE vaccine CI brief — competitive landscape report
- JE vaccine updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI